Research programme: Liver regeneration therapeutics - Omega Therapeutics
Latest Information Update: 28 Nov 2022
Price :
$50 *
At a glance
- Originator Omega Therapeutics
- Class Hepatoprotectants; RNA
- Mechanism of Action Hepatocyte nuclear factor 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver disorders
Most Recent Events
- 22 Nov 2022 Preclinical trials in Liver disorders in USA (IV) (Omega therapeutics website, November 2022)
- 22 Nov 2022 Pharmacodynamics data from preclinical studies in Liver disorders released by Omega Therapeutics (Omega therapeutics website, November 2022)
- 30 Jun 2021 Omega Therapeutics in-licensed one issued US patent, 11 non-provisional US patent applications and two provisional US patent applications; four PCT patent applications; and 22 foreign patent applications in Europe, Australia, Canada, China, Hong Kong, Japan, and Mexico